{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:54:27Z","timestamp":1785128067189,"version":"3.55.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To provide the latest systematic review and meta-analysis comparing the effectiveness and safety of tofacitinib and adalimumab in rheumatoid arthritis (RA) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of PubMed, Embase, Web of Science, and Cochrane databases was conducted until April 2025. Randomized controlled trials and cohorts comparing tofacitinib and adalimumab in RA patients were included. Outcomes assessed were significant improvements in American College of Rheumatology (ACR) 20 improvement criteria, changes in visual analog scale (VAS) (global activity), disease activity score (DAS) 28-C-reactive protein (CRP), Health Assessment Questionnaire-Disability Index (HAQ-DI), and adverse events. Sensitivity analyses and subgroup analysis evaluated the robustness of results and heterogeneity. Data analysis was performed using Review Manager 5.4.1 and STATA 15.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Nine studies with 24,643 patients were analyzed. Tofacitinib showed superior effectiveness over adalimumab in ACR20 (risk ratio (RR): 1.28; 95% CI: 1.06, 1.55; P = 0.01), HAQ-DI (standardized mean difference (SMD): 0.20; 95% CI: 0.35, \u22120.05; P = 0.008), and VAS (SMD: 0.30; 95% CI: 0.56, \u22120.03; P = 0.03). No significant differences were found in adverse events (RR: 0.96; 95% CI: 0.89, 1.03; P = 0.22) or DSA28-CRP improvement (SMD: 0.02; 95% CI: 0.45, 0.02; P = 0.07). Sensitivity analyses confirmed stable outcomes for adverse events, HAQ-DI, and ACR20, but instability for VAS and DSA28-CRP. Subgroup analysis found that tofacitinib &amp;gt;5\u00a0mg twice daily was superior to \u22645\u00a0mg in terms of ACR20.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Tofacitinib was more effective than adalimumab in improving ACR20, VAS, and HAQ-DI, with no significant differences in adverse events or DSA28-CRP improvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration:<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1524214","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:24:57Z","timestamp":1749446697000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparative effectiveness and safety of tofacitinib vs. adalimumab in patients with rheumatoid arthritis: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Chunyan","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zilu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guozong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s41927-024-00414-6","article-title":"Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis","volume":"8","author":"Adami","year":"2024","journal-title":"BMC Rheumatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e233640","DOI":"10.1001\/jamanetworkopen.2023.3640","article-title":"Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-modifying antirheumatic drugs","volume":"6","author":"Baker","year":"2023","journal-title":"JAMA Netw. open"},{"key":"B3","first-page":"S102","article-title":"One-year medication adherence and persistence in patients with rheumatoid arthritis in clinical practice: retrospective analysis of upadacitinib, adalimumab, baricitinib, and tofacitinib","volume":"28","author":"Bergman","year":"2022","journal-title":"J. Manag. Care Specialty Pharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/319516a0","article-title":"Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors","volume":"319","author":"Bertolini","year":"1986","journal-title":"Nature"},{"key":"B5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.2174\/0115748863300565240819114551","article-title":"Tofacitinib-induced acute pancreatitis in a patient with rheumatoid arthritis: a case report and review of the literature","volume":"20","author":"Boussaa","year":"2024","journal-title":"Curr. Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e15311","DOI":"10.1111\/1756-185X.15311","article-title":"A retrospective study of efficacy of tofacitinib combined with bDMARDs in the treatment of rheumatoid arthritis patients with inadequate response to bDMARDs","volume":"27","author":"Chang","year":"2024","journal-title":"Int. J. rheumatic Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus Kinase (JAK) inhibitors for inflammatory diseases: miniperspective","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"B8","doi-asserted-by":"publisher","first-page":"7264704","DOI":"10.1155\/2024\/7264704","article-title":"Lipocalin-2 serum levels in rheumatoid arthritis patients treated with adalimumab and its correlation with proinflammatory factors","volume":"2024","author":"Conde-Aranda","year":"2024","journal-title":"Mediat. Inflamm."},{"key":"B9","doi-asserted-by":"publisher","first-page":"Ed000142","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane database Syst. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e2320851","DOI":"10.1001\/jamanetworkopen.2023.20851","article-title":"Comparative effectiveness of adalimumab vs tofacitinib in patients with rheumatoid arthritis in Australia","volume":"6","author":"Deakin","year":"2023","journal-title":"JAMA Netw. open"},{"key":"B12","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/art.33383","article-title":"Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs","volume":"64","author":"Fleischmann","year":"2012","journal-title":"Arthritis rheumatism"},{"key":"B13","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann","year":"2017","journal-title":"Lancet London, Engl."},{"key":"B14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.55563\/clinexprheumatol\/3f60yv","article-title":"Cost-utility of tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis in France: a multi-state Markov model analysis","volume":"43","author":"Fournier","year":"2024","journal-title":"Clin. Exp. rheumatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e004622","DOI":"10.1136\/rmdopen-2024-004622","article-title":"The effect of rituximab on patient reported outcomes in the preclinical phase of rheumatoid arthritis: 2 year data from the PRAIRI study","volume":"10","author":"Frazzei","year":"2024","journal-title":"RMD open"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1461756","DOI":"10.3389\/fimmu.2024.1461756","article-title":"Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective","volume":"15","author":"Han","year":"2024","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13075-023-03047-1","article-title":"Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab","volume":"25","author":"Kim","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/nu11040826","article-title":"Effect of red, processed, and white meat consumption on the risk of gastric cancer: an overall and dose-response meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Nutrients"},{"key":"B20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/0115748863274863231222023853","article-title":"Tumor necrosis alpha (TNF-\u03b1) antagonists used in chronic inflammatory rheumatic diseases: risks and their minimization measures","volume":"19","author":"Lakhmiri","year":"2024","journal-title":"Curr. Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3324\/haematol.2014.109884","article-title":"Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease","volume":"100","author":"Laverdi\u00e8re","year":"2015","journal-title":"haematologica"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e004687","DOI":"10.1136\/rmdopen-2024-004687","article-title":"Combining patient-reported outcome measures to screen for active disease in rheumatoid arthritis and psoriatic arthritis","volume":"10","author":"Looijen","year":"2024","journal-title":"RMD open"},{"key":"B23","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ Clin. Res. ed"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1482214","DOI":"10.3389\/fimmu.2024.1482214","article-title":"The gut homeostasis-immune system axis: novel insights into rheumatoid arthritis pathogenesis and treatment","volume":"15","author":"Qi","year":"2024","journal-title":"Front. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1007\/s10067-024-07161-6","article-title":"Incidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: a population-based cohort study","volume":"43","author":"Shih","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e14182","DOI":"10.1111\/jep.14182","article-title":"The role of patient reported symptom data in co-producing meaning in rheumatoid arthritis","volume":"31","author":"Skyrme","year":"2024","journal-title":"J. Eval. Clin. Pract."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1093\/rheumatology\/keae435","article-title":"Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis","volume":"63","author":"Smolen","year":"2024","journal-title":"Rheumatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1080\/14656566.2024.2412247","article-title":"Rheumatoid arthritis in Latin America: pharmacotherapy and clinical challenges","volume":"25","author":"Soriano","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e001040","DOI":"10.1136\/rmdopen-2019-001040","article-title":"Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB\/IV trial","volume":"5","author":"Strand","year":"2019","journal-title":"RMD open"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/rheumatology\/kev442","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis","volume":"55","author":"Strand","year":"2016","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B31","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13075-021-02591-y","article-title":"Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy","volume":"23","author":"Takeuchi","year":"2021","journal-title":"Arthritis Res. & Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"New Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e004472","DOI":"10.1136\/rmdopen-2024-004472","article-title":"On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis","volume":"10","author":"Vittecoq","year":"2024","journal-title":"RMD open"},{"key":"B34","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses\n          \n          \n            \n              Wells\n              G.\n            \n            \n              Shea\n              B.\n            \n            \n              O'Connell\n              D.\n            \n            \n              Peterson\n              J.\n            \n            \n              Welch\n              V.\n            \n            \n              Losos\n              M.\n            \n          \n          \n          2011"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3390\/ph17081028","article-title":"Adverse event profiles of adalimumab in children: a disproportionality analysis","volume":"17","author":"Zhang","year":"2024","journal-title":"Pharm. Basel, Switz."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1466023","DOI":"10.3389\/fimmu.2024.1466023","article-title":"The role of cGAS-STING signaling in rheumatoid arthritis: from pathogenesis to therapeutic targets","volume":"15","author":"Zhu","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1524214\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:24:58Z","timestamp":1749446698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1524214\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":35,"alternative-id":["10.3389\/fphar.2025.1524214"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1524214","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"article-number":"1524214"}}